Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP Inhibitor”

312 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 312 results

Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Testing effectiveness (Phase 2)UnknownNCT05489926
What this trial is testing

Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure

Who this might be right for
Epithelial Ovarian Cancer
Zhejiang Cancer Hospital 15
Large-scale testing (Phase 3)Active Not RecruitingNCT04380636
What this trial is testing

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 870
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05232006
What this trial is testing

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

Who this might be right for
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
Assistance Publique - Hôpitaux de Paris 12
Testing effectiveness (Phase 2)Study completedNCT02952534
What this trial is testing

Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 277
Testing effectiveness (Phase 2)Study completedNCT04174716
What this trial is testing

Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors (VASTUS)

Who this might be right for
Solid TumorsHomologous Recombination Repair Gene MutationHomologous Recombination Deficiency
Idience Co., Ltd. 108
Not applicableNot Yet RecruitingNCT06572735
What this trial is testing

Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Hospices Civils de Lyon 50
Testing effectiveness (Phase 2)Ended earlyNCT05501548
What this trial is testing

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 4
Testing effectiveness (Phase 2)Looking for participantsNCT06380660
What this trial is testing

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultBRCA1 MutationBRCA2 Mutation+3 more
Acerand Therapeutics (Shanghai) Limited 298
Testing effectiveness (Phase 2)Active Not RecruitingNCT04644068
What this trial is testing

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Who this might be right for
Ovarian CancerBreast CancerPancreatic Cancer+10 more
AstraZeneca 702
Testing effectiveness (Phase 2)Study completedNCT02657889
What this trial is testing

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

Who this might be right for
NeoplasmsTriple Negative Breast CancerOvarian Cancer+6 more
Tesaro, Inc. 122
Testing effectiveness (Phase 2)Looking for participantsNCT06525298
What this trial is testing

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Who this might be right for
Advanced Solid TumorHomologous Recombination DeficiencyHRR Deficiency
Eisbach Bio GmbH 144
Early research (Phase 1)Looking for participantsNCT05787587
What this trial is testing

PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+6 more
IDEAYA Biosciences 216
Early research (Phase 1)Looking for participantsNCT06121557
What this trial is testing

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 24
Early research (Phase 1)Looking for participantsNCT05053854
What this trial is testing

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Who this might be right for
Neuroendocrine Tumors
Peter MacCallum Cancer Centre, Australia 24
Early research (Phase 1)Study completedNCT01445522
What this trial is testing

ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer

Who this might be right for
NeoplasmsLymphoma
National Cancer Institute (NCI) 35
Early research (Phase 1)Study completedNCT01345357
What this trial is testing

Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma

Who this might be right for
Solid Tumors or Mantle Cell Lymphoma
Cephalon 24
Early research (Phase 1)WithdrawnNCT05262842
What this trial is testing

JS001+IMP4297 in Patients With Advanced Cancer

Who this might be right for
Advanced Cancer
Shanghai Junshi Bioscience Co., Ltd.
Testing effectiveness (Phase 2)Study completedNCT01989546
What this trial is testing

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Who this might be right for
Advanced Ovarian CancerPrimary Peritoneal CancerAdvanced Breast Cancer+1 more
National Cancer Institute (NCI) 9
Not applicableLooking for participantsNCT06197581
What this trial is testing

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Who this might be right for
Breast Cancer, Familial MaleRadiotherapy; ComplicationsChemotherapeutic Toxicity+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 148
Load More Results